Dayvigo and DORAs recently has been talked about by Dr. Matt Walker as the drug seems to have helo to clear alzheimer’s related proteins.
Tim Ferris is using Belsomra for the same reason. Bryan Johnson tried Dayvigo.
If you must use sleep meds for sleep maintaince, this may be one of less evil one.
Mechanistically, it makes sense as Dayvigo or DORAs reduce “the wake” signal while you sleep.
Anyone? There are plenty DORAs papers out there talked about the alzheimer angle.
I saw this recently on X, has anyone tried these for sleep?
The scientific evidence supporting the use of CJC-1295 and Ipamorelin for sleep improvement is primarily mechanistic and extrapolated from studies on their endogenous counterparts (Growth Hormone-Releasing Hormone and Ghrelin) or related secretagogues (like MK-677).
While clinical wellness protocols frequently prescribe this stack to enhance sleep quality—specifically Slow-Wave Sleep (SWS) and REM—direct Randomized Controlled Trials (RCTs) quantifying sleep architecture changes specifically for this combination in healthy adults are largely absent from the peer-reviewed literature.
The following analysis details the evidence for each compound based on its pharmacological class.
Mechanism: GHRH Agonism Slow-Wave Sleep (SWS) Promotion
CJC-1295 is a long-acting analog of Growth Hormone-Releasing Hormone (GHRH). The strongest evidence for sleep improvement lies in the well-established neurobiology of endogenous GHRH, which acts as a sleep-promoting substance.
GHRH and Slow-Wave Sleep: Extensive research demonstrates a causal link between GHRH and the regulation of Non-Rapid Eye Movement (NREM) sleep.
Intravenous administration of GHRH in humans has been shown to robustly increase Slow-Wave Sleep (Stages 3 and 4), particularly when administered in the latter part of the night [1].
Conversely, the administration of GHRH antagonists (which block GHRH receptors) significantly suppresses SWS and growth hormone secretion, suggesting GHRH is essential for normal sleep depth [2].
Clinical Extrapolation: While CJC-1295 extends the half-life of GHRH via Drug Affinity Complex (DAC) or modified pharmacokinetics, it activates the same receptors. Therefore, the claim that CJC-1295 improves deep sleep is scientifically plausible based on the GHRH-SWS axis, even in the absence of a CJC-1295 specific polysomnography trial.
Mechanism: Ghrelin Receptor (GHS-R1a) Agonism Potential REM/SWS Modulation
Ipamorelin is a selective agonist of the ghrelin receptor. The evidence for its impact on sleep is more complex and derived largely from data on Ghrelin and other secretagogues like MK-677 (Ibutamoren).
Ghrelin and Sleep Architecture: Ghrelin is an endogenous sleep-promoting factor. Studies indicate that ghrelin administration in humans can increase SWS and enhance delta-wave activity [3].
The “Class Effect” Evidence:
MK-677 (Ibutamoren): A non-peptide ghrelin mimetic (functionally similar to Ipamorelin but orally active and longer-lasting) has demonstrated clear clinical efficacy in sleep. A double-blind, placebo-controlled trial found that MK-677 treatment increased REM sleep by and Stage IV sleep (deep sleep) by in young adults () [4].
GHRP-2: Conversely, other peptides in this class (e.g., GHRP-2) have shown no significant effect on sleep architecture in some trials, despite raising GH levels [5].
Ipamorelin Specifics: Ipamorelin is distinct because of its high selectivity for the GH release pathway with minimal impact on cortisol or ACTH (unlike GHRP-2 or GHRP-6). While this makes it “cleaner” for metabolic use, there is a knowledge gap regarding its specific independent effect on sleep stages compared to the broader, “dirtier” secretagogues like MK-677 which have stronger clinical sleep data.
In longevity and performance medicine, these two peptides are stacked to mimic physiological pulsatility: CJC-1295 provides the basal GHRH “tone” (supporting SWS), while Ipamorelin provides the pulse (supporting GH release).
| Compound | Primary Sleep Target (Theoretical) | Strength of Mechanistic Evidence | Direct Clinical Trial Data |
|---|---|---|---|
| CJC-1295 | Slow-Wave Sleep (Deep) | High (via GHRH studies) | Low (Extrapolated) |
| Ipamorelin | REM & SWS | Moderate (via Ghrelin studies) | Very Low (Inferred from MK-677) |
Scholarly Debate & Nuance:
There is strong mechanistic evidence that the GHRH pathway (targeted by CJC-1295) regulates Deep Sleep (SWS), and moderate clinical evidence from related compounds (MK-677) that the ghrelin pathway (targeted by Ipamorelin) can improve REM and sleep quality. However, specific peer-reviewed RCTs validating the sleep architecture effects of the CJC-1295 + Ipamorelin stack remain a data gap. Current clinical confidence is based on the verified pharmacodynamics of their receptor targets rather than direct outcome studies.
[1] Evidence against a role for the growth hormone-releasing peptide axis in human slow-wave sleep regulation (Comparison of GHRH vs GHRP effects)
[2] Blockade of endogenous growth hormone-releasing hormone receptors dissociates nocturnal growth hormone secretion and slow-wave sleep
[3] Ghrelin promotes slow-wave sleep in humans
[4] Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man
[5] Ipamorelin, the first selective growth hormone secretagogue (Selectivity profile)
[6] Complex relationship between growth hormone and sleep in children: insights, discrepancies, and implications
This is the problem with many “research” peptides, not much in the way of peer reviewed studies. Lots of mechanistic based speculation though, which is not terrible, as that is always the starting point.
Personally, this combo IPA + CJC 1295 noDAC is one of my staples and have been taking it for 2.5 years, 5 nights a week, with a few breaks. Sleep is my super power, always has been, so I never noticed a difference, thus no opinion on the effect it might have on my sleep.
There are a lot of N-1 reports that it has improved sleep for other people. And it may have improved sleep for my wife who, as a mother of 4, became a very light sleeper and carried that through long after they left the nest. Over the last 2 years she has become a decent (not great but way better) sleeper and it may be due to IPA+CJC but I can’t say for sure.
We started tracking sleep too late to know what her sleep was really like before IPA+CJC.
When we did start tracking sleep as we prepared to evaluate DSIP, we have also seen a distinct benefit from this one, it has consolidated our deep sleep and increased the amount of DS significantly.
Had a quote to buy 100 pills of 5mg Dayvigo at $63 from India.
It seems to be pretty high price?
That sounds like an exceptionally good price actually!
